Cytosorbents Corporation
NASDAQ:CTSO
0.8622 (USD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 36.349 | 29.36 | 40.109 | 39.453 | 22.766 | 20.252 | 13.382 | 8.206 | 4.056 | 3.145 | 0.822 | 0.152 | 0.036 | 0 | 0 | 0 | 0 | 0 | 0.01 |
Cost of Revenue
| 13.957 | 13.956 | 11.048 | 11.053 | 7.364 | 7.489 | 5.518 | 3.954 | 2.213 | 2.134 | 1.912 | 0.319 | 0.012 | 0 | 0 | 0 | 0 | 0 | 0.01 |
Gross Profit
| 22.392 | 15.404 | 29.061 | 28.4 | 15.402 | 12.763 | 7.863 | 4.252 | 1.843 | 1.011 | -1.09 | -0.168 | 0.024 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit Ratio
| 0.616 | 0.525 | 0.725 | 0.72 | 0.677 | 0.63 | 0.588 | 0.518 | 0.454 | 0.321 | -1.326 | -1.107 | 0.674 | 0 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 15.729 | 15.119 | 16.381 | 8.81 | 12.092 | 7.723 | 4.049 | 4.783 | 3.871 | 2.432 | 1.739 | 2.532 | 2.888 | 1.757 | 1.962 | 1.983 | 1.416 | 1.113 | 0 |
General & Administrative Expenses
| 37.872 | 37.136 | 38.482 | 31.512 | 24.468 | 22.876 | 15.426 | 12.283 | 8.012 | 6.836 | 3.485 | 1.982 | 1.573 | 1.067 | 0.757 | 0.909 | 1.651 | 0.939 | 0.07 |
Selling & Marketing Expenses
| -4.272 | 0.582 | 0.615 | 0.285 | 0.314 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.308 | 0.351 | 0 | 0.912 | 0 |
SG&A
| 33.6 | 37.136 | 38.482 | 31.512 | 24.468 | 22.876 | 15.426 | 12.283 | 8.012 | 6.836 | 3.485 | 1.982 | 1.573 | 1.067 | 1.065 | 1.261 | 1.651 | 1.852 | 0.07 |
Other Expenses
| -3.616 | -5.329 | -3.057 | -1.552 | -2.184 | -2.252 | -1.769 | -1.322 | -0.736 | -2.428 | -1.601 | -1.191 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 |
Operating Expenses
| 52.945 | 46.926 | 51.806 | 38.77 | 34.376 | 28.348 | 17.706 | 15.744 | 11.147 | 8.29 | 3.623 | 3.323 | 4.461 | 2.824 | 3.027 | 3.244 | 3.067 | 2.964 | 0.08 |
Operating Income
| -30.553 | -31.522 | -22.745 | -10.37 | -18.974 | -15.585 | -9.843 | -11.492 | -9.304 | -7.279 | -4.713 | -3.491 | -4.437 | -2.824 | -2.43 | -3.244 | -3.067 | -2.964 | -0.08 |
Operating Income Ratio
| -0.841 | -1.074 | -0.567 | -0.263 | -0.833 | -0.77 | -0.736 | -1.4 | -2.294 | -2.314 | -5.735 | -23.031 | -122.977 | 0 | 0 | 0 | 0 | 0 | -8 |
Total Other Income Expenses Net
| 1.232 | -2.383 | -2.55 | 1.406 | -1.384 | -0.785 | 1.454 | -0.533 | 0.838 | -2.428 | -0.846 | -0.564 | -1.045 | 5.818 | 6.071 | -0.022 | -0.351 | 0.032 | 0 |
Income Before Tax
| -29.321 | -33.905 | -25.295 | -8.964 | -20.358 | -17.831 | -9.138 | -12.257 | -8.456 | -9.707 | -5.136 | -4.055 | -5.482 | 2.909 | 3.036 | -3.266 | -3.351 | -7.672 | -0.08 |
Income Before Tax Ratio
| -0.807 | -1.155 | -0.631 | -0.227 | -0.894 | -0.88 | -0.683 | -1.494 | -2.085 | -3.086 | -6.25 | -26.754 | -151.939 | 0 | 0 | 0 | 0 | 0 | -8 |
Income Tax Expense
| -0.814 | -1.092 | -0.736 | -1.127 | -1.092 | -0.62 | -0.677 | -0.319 | -0.325 | -0.386 | -0.458 | -0.392 | 1.045 | 5.818 | 0.299 | -0.249 | 3.351 | 7.672 | 0 |
Net Income
| -28.507 | -32.813 | -24.559 | -7.837 | -19.266 | -17.211 | -8.461 | -11.939 | -8.132 | -9.321 | -4.678 | -3.664 | -5.482 | -2.909 | -2.737 | -3.018 | -3.351 | -7.672 | -0.08 |
Net Income Ratio
| -0.784 | -1.118 | -0.612 | -0.199 | -0.846 | -0.85 | -0.632 | -1.455 | -2.005 | -2.964 | -5.692 | -24.17 | -151.939 | 0 | 0 | 0 | 0 | 0 | -8 |
EPS
| -0.64 | -0.75 | -0.57 | -0.2 | -0.6 | -0.56 | -0.31 | -0.47 | -0.33 | -0.65 | -0.5 | -0.46 | -0.86 | -0.74 | -1.64 | -3 | -3.37 | -12.82 | -0.26 |
EPS Diluted
| -0.64 | -0.75 | -0.57 | -0.2 | -0.6 | -0.56 | -0.31 | -0.47 | -0.33 | -0.65 | -0.5 | -0.46 | -0.86 | -0.74 | -1.64 | -3 | -3.37 | -12.82 | -0.26 |
EBITDA
| -28.526 | -29.073 | -20.167 | -10.37 | -18.974 | -15.194 | -11.078 | -10.797 | -10.029 | -7.279 | -4.649 | -3.436 | -4.398 | 3.012 | 3.095 | -3.141 | -2.525 | -1.74 | -0.07 |
EBITDA Ratio
| -0.785 | -0.99 | -0.503 | -0.263 | -0.833 | -0.75 | -0.828 | -1.316 | -2.473 | -2.314 | -5.657 | -22.67 | -121.892 | 0 | 0 | 0 | 0 | 0 | -7 |